Core Points - The Rosen Law Firm is reminding investors who purchased CoreWeave, Inc. securities between March 28, 2025, and December 15, 2025, of a lead plaintiff deadline on March 13, 2026 [1] - Investors may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [1] - A class action lawsuit has been filed against CoreWeave, alleging that the company made false and misleading statements regarding its ability to meet customer demand and the risks associated with reliance on a single third-party data center supplier [1] Legal Context - The lawsuit claims that CoreWeave overstated its capacity to meet customer demand and understated the risks related to its data center supplier, which could negatively impact revenue [1] - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [1] - The Rosen Law Firm has a history of significant settlements in securities class actions, including a record settlement against a Chinese company [1]

Core Points - CoreWeave, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934 during the class period from March 28, 2025, to December 15, 2025 [1] - The lawsuit claims that CoreWeave and its executives made misleading statements regarding the company's ability to meet customer demand and the risks associated with reliance on a single third-party data center supplier [1] - Significant events leading to the lawsuit include a failed merger with Core Scientific, which caused a share price drop of over 6%, and a subsequent revenue guidance reduction that led to a further decline of more than 16% in share price [1] Company Overview - CoreWeave is positioned as an AI cloud computing company and had announced a deal worth up to $11.9 billion with OpenAI shortly before its IPO [1] - The company also attempted to acquire Core Scientific, a major player in digital infrastructure for high-performance computing, in an all-stock transaction [1] Allegations and Impact - The lawsuit alleges that CoreWeave overstated its service capabilities and downplayed the risks associated with its data center supplier, which were likely to negatively impact revenue [1] - On October 30, 2025, Core Scientific announced it did not have enough shareholder votes to approve the merger with CoreWeave, leading to a significant drop in CoreWeave's stock price [1] - Following a revenue guidance cut on November 10, 2025, due to delays from a third-party data center developer, CoreWeave's CEO acknowledged that multiple data centers were affected, resulting in a further stock price decline [1] - A December 15, 2025, article from The Wall Street Journal revealed more severe data center delivery issues than previously disclosed, causing an additional 3.4% drop in share price [1]

Group 1 - Phemex has completed the full integration of Ondo Finance's tokenized equity suite, positioning itself as a leader in the Real-World Asset (RWA) revolution [1] - The platform now offers its 10 million global users seamless access to a diverse selection of 14 traditional blue-chip assets in tokenized form, including major companies like NVIDIA, Tesla, Apple, and Amazon [1] - This strategic initiative emphasizes Phemex's commitment to accelerating the convergence of Traditional Finance (TradFi) and Web3, enhancing capital efficiency and portfolio diversification for users [1] Group 2 - Phemex, founded in 2019, is a user-centric cryptocurrency platform trusted by over 10 million traders worldwide, offering spot and derivatives trading, copy trading, and asset management products [1] - The platform aims to provide reliable tools, inclusive access, and evolving opportunities for traders at all levels, prioritizing user experience, transparency, and innovation [1]

Core Insights - Johnson & Johnson announced long-term data from the QUASAR study showing that TREMFYA® (guselkumab) maintains clinical and endoscopic remission in ulcerative colitis patients over three years, with over 80% of patients in clinical remission and more than 50% in endoscopic remission at Week 140 [1][2]. Group 1: Clinical Efficacy - At Week 140, 80.8% of patients treated with TREMFYA® were in clinical remission, while 53.6% achieved endoscopic remission [1]. - 78.6% of patients experienced histo-endoscopic mucosal improvement (HEMI), indicating significant intestinal healing [1]. - Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140, demonstrating sustained efficacy [1]. Group 2: Study Retention and Safety - Approximately 89% of eligible study participants completed treatment through Week 140, indicating high retention rates [1]. - No new safety concerns were reported during the study, reinforcing the long-term safety profile of TREMFYA® [1][2]. Group 3: Mechanism and Approval - TREMFYA® is the first and only approved dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, targeting immune-mediated diseases [1][2]. - The drug has received FDA and European Commission approval for treating both moderately to severely active Crohn's disease and ulcerative colitis [1][2]. Group 4: Additional Research and Commitment - Johnson & Johnson presented 30 abstracts at the European Crohn's and Colitis Organisation (ECCO) 2026 conference, highlighting ongoing research and commitment to inflammatory bowel disease treatments [1]. - Two other abstracts from Johnson & Johnson were recognized as Top 10 oral abstracts, showcasing the company's dedication to advancing treatment options [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bath & Body Works, Inc. related to securities purchased between June 4, 2024, and November 19, 2025, and is encouraging affected investors to discuss their legal options [1] Group 1 - The law firm reminds investors of the March 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against Bath & Body Works [1]

Core Viewpoint - Vistagen Therapeutics is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug fasedienol, leading to significant financial losses for investors [1][1]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics and has set a deadline of March 16, 2026, for investors to seek the role of lead plaintiff in the class action [1]. - The lawsuit claims that Vistagen and its executives violated federal securities laws by failing to disclose material adverse facts about the drug fasedienol's trial results [1][1]. - Following the announcement of the failed PALISADE-3 clinical trial results, Vistagen's stock price plummeted over 81%, opening at $0.88 per share [1][1]. Group 2: Clinical Trial Results - On December 17, 2025, Vistagen reported that its PALISADE-3 study did not meet its primary efficacy endpoint, failing to show statistically significant improvement in reducing anxiety compared to placebo [1][1]. - The positive assertions made by Vistagen regarding fasedienol's future trial success were deemed false and misleading, contributing to the inflated stock prices prior to the announcement [1][1]. Group 3: Investor Information - Investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights [1][1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [1][1].

Core Insights - PureHealth Research has introduced supplements for lymphatic system support that utilize Dandelion and Burdock Root in a "Flush and Filter" approach to combat unexplained swelling [1] Group 1: Lymphatic System Function - The lymphatic system lacks a central pump and relies on muscle movement and breathing for lymph fluid circulation, leading to potential fluid buildup and a feeling of puffiness when flow slows [1] - Lymphatic congestion can impair immune response as lymph nodes struggle to filter harmful substances effectively when fluid movement is hindered [1] Group 2: Ingredients and Benefits - Dandelion Extract offers gentle diuretic action to reduce excess fluid without depleting potassium levels, making it safer for daily use compared to harsh diuretics [1] - Burdock Root aids in blood purification and supports liver and kidney function during lymphatic drainage, creating a comprehensive flush-and-filter system [1] - The supplements also include additional botanicals like Echinacea and Cleavers to enhance natural drainage pathways and promote healthy fluid balance and immune function [1]

Core Insights - CHAI has achieved a remarkable 3X annual growth rate, reaching $68 million in Annual Recurring Revenue (ARR) and a valuation of $1.4 billion over the past three years [1][1][1] Company Growth - The company has experienced phenomenal momentum, indicating strong market demand and user engagement [1][1] - CHAI's growth trajectory reflects its commitment to providing an engaging platform for users to create and interact with customized chatbots [1][1] AI Safety Measures - CHAI emphasizes the importance of safety in AI, investing significantly in ensuring platform security as it scales [1][1] - The company aligns its safety protocols with global standards, including the EU AI Act and the NIST AI Risk Management Framework [1][1] - A moderation system is in place to filter out harmful content, and an advanced real-time classifier is developed to detect suicidal ideation or self-harm scenarios [1][1] User Support and Transparency - CHAI's AI is designed to respond compassionately to users expressing suicidal or self-harm thoughts, directing them to appropriate human support [1][1] - The platform logs user interactions on secure servers, conducting anonymized reviews to identify risks while maintaining user privacy [1][1] - The company aims to set a precedent for user safety and ethical technology use, collaborating with safety experts to enhance its safety framework [1][1]

Core Viewpoint - Rosen Law Firm is reminding former stockholders of Smartsheet Inc. about a class action lawsuit related to the company's January 2025 sale to a consortium led by Blackstone, Vista Equity Partners, and Platinum Falcon, with a lead plaintiff deadline of February 24, 2026 [1] Group 1: Class Action Details - Former Smartsheet stockholders may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 24, 2026 [1] - The complaint alleges that Smartsheet's solicitation of stockholder approval for the Buyout involved a false and misleading Proxy statement that mischaracterized the company's financial performance [1] Group 2: Allegations Against Defendants - The defendants are accused of intentionally portraying Smartsheet's quarterly earnings negatively and emphasizing a fabricated financial metric to solicit approval for the Buyout [1] - Mark P. Mader, a defendant, is alleged to have failed in his disclosure duties by not exercising reasonable care [1] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for settlements since 2013 [1] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Apollo Global Management, Inc. due to allegations of misleading business information [1] Group 1: Investigation Details - The investigation is prompted by an article from Financial Times stating that Apollo executives, including CEO Marc Rowan, discussed tax arrangements with Jeffrey Epstein throughout the 2010s, contradicting previous claims that the firm "never did any business" with Epstein [1] - Following the news, Apollo's stock experienced a decline of 1% on February 2, 2026, and a further drop of 4.76% on February 3, 2026 [1] Group 2: Class Action Information - Investors who purchased Apollo securities may be entitled to compensation through a contingency fee arrangement, allowing them to join the class action without upfront costs [1] - Interested investors can join the prospective class action by visiting the provided link or contacting Rosen Law Firm directly [1] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [1] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [1]